ADC Therapeutics Q3 net income beats analyst expectations

Overview

• ADC Therapeutics Q3 net income and income from operations beat analyst expectations

• Net product revenues for Q3 2025 declined due to lower sales volume

• Completed $60 mln PIPE financing to expand ZYNLONTA and strengthen balance sheet

Outlook

• ADC Therapeutics expects LOTIS-7 data by end of 2025

• Company anticipates LOTIS-5 topline results in 1H 2026

• Recent financing extends cash runway into 2028

Result Drivers

• PIPE FINANCING - Completed $60 mln PIPE financing to support ZYNLONTA expansion and strengthen balance sheet

• REVENUE DECLINE - Lower sales volume led to a decline in Q3 net product revenues despite higher prices

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for ADC Therapeutics SA is $7.50, about 46.1% above its November 7 closing price of $4.04

Press Release: ID:nPn8rfSYRa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)